Lavender Essential Oil-based Product System for Sleep
Public ClinicalTrials.gov record NCT06510335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of a Lavender-based Natural Product System for Sleep Support
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn whether lavender essential oil-based product system can affect gene expression, serum protein markers, and sleep quality in healthy volunteers. The main questions this study aims to answer are: * Does the lavender essential oil-based product system affect gene expression and protein markers as measured in blood? * Does the lavender essential oil-based product system affect subjective quality of life and sleep assessments? * Is daily use of the product system safe, as measured by laboratory tests and adverse events? The lavender essential oil-based product system contains three components: an essential oil blend, a topical stick, and a dietary supplement. Participants will: * Receive a fitness tracker to monitor their sleep and physical activity. * Use the lavender essential oil-based product system for six weeks total according to this schedule: * 1 week: Essential oil blend * 1 week: Essential oil blend + topical stick * 4 weeks: Essential oil blend + topical stick + dietary supplement * Attend two study visits in which they provide blood and urine samples, and complete subjective sleep and quality of life assessments * Complete weekly subjective sleep assessments from home
Study identification
- NCT ID
- NCT06510335
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2023
- Primary completion
- Jul 31, 2023
- Completion
- Aug 10, 2023
- Last update posted
- Jul 21, 2024
2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| doTERRA International | Pleasant Grove | Utah | 84062 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06510335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06510335 live on ClinicalTrials.gov.